Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026

Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE

This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization

Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP

The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

We are building the bridge between complex molecular data and everyday clinical decisions

Aragen scales Renaissance Pharma’s cancer antibody to commercial GMP in just 9 months

Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

OneSource Specialty Pharma's partners get Health Canada approval for generic Semaglutide injection

Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing

OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide

Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility

CENT launches advanced clinical prevention centre in Bengaluru, partners Siemens Healthineers

Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally